Wide Ranks

HEPA

Hepion Pharmaceuticals, Inc.

0.6410

Top Statistics
Market Cap 4 M Forward PE -0.0561 Revenue Growth 0.00 %
Current Ratio 5.62 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.1170 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 2 M Total Cash Per Share 0.3650 Total Debt 154090
Total Debt To Equity 4.33 Current Ratio 5.62 Book Value Per Share 1.16
All Measures
Short Ratio 92.00 % Message Board Id finmb_244424098 Fax 732 902 4100
Shares Short Prior Month 25113 Return On Equity -1.90 City Edison
Uuid bec39233-f713-3fce-8d16-915e909efc3e Previous Close 0.6701 First Trade Date Epoch Utc 1 B
Book Value 1.16 Beta 1.81 Total Debt 154090
Volume 22232 Price To Book 0.5531 Last Split Date 1 B
Fifty Two Week Low 0.5530 Total Cash Per Share 0.3650 Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Net Income To Common -28365592
Short Percent Of Float 0.0113 Implied Shares Outstanding 6 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 26300 Average Volume10days 26300
Total Cash 2 M Next Fiscal Year End 1 B Held Percent Insiders 0.0008
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.6701 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.6625 Open 0.6660 Free Cashflow -26445260
State NJ Dividend Yield 0.00 % Return On Assets -0.9282
Time Zone Short Name EST Trailing Eps -4.40 Day Low 0.6200
Address1 399 Thornall Street Shares Outstanding 6 M Price Hint 4
Target High Price 0.0000 Website https://hepionpharma.com 52 Week Change -0.8009
Average Volume 41562 Forward Eps -11.43 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 216.80 % Last Split Factor 1:20
Regular Market Day High 0.6751 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 4.33 Fifty Two Week High 4.47 Day High 0.6751
Shares Short 65726 Regular Market Open 0.6660 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0113
Operating Cashflow -34783512 Currency USD Time Zone Full Name America/New_York
Market Cap 4 M Is_nasdaq_100 False Zip 08837
Quote Type EQUITY Industry Biotechnology Long Name Hepion Pharmaceuticals, Inc.
Regular Market Day Low 0.6200 Held Percent Institutions 0.0785 Current Price 0.6410
Address2 First Floor Enterprise To Ebitda -0.1170 Financial Currency USD
Current Ratio 5.62 Industry Disp Biotechnology Country United States
Float Shares 5 M Two Hundred Day Average 1.23 Enterprise Value 3 M
Forward PE -0.0561 Regular Market Volume 22232 Ebitda -31507800
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.

It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.

The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.

Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.